Vir Biotechnology (VIR) News Today → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free VIR Stock Alerts $10.27 -0.12 (-1.15%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 29, 2024 | finance.yahoo.comVir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceMay 29, 2024 | businesswire.comVir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceMay 29, 2024 | msn.comResearchers discover vaccine originally created for HIV may also combat cancerMay 29, 2024 | markets.businessinsider.comVir Biotechnology Appoints Mark Eisner As EVP And Chief Medical OfficerMay 29, 2024 | americanbankingnews.comVir Biotechnology, Inc. (NASDAQ:VIR) Receives Consensus Rating of "Moderate Buy" from AnalystsMay 29, 2024 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Rating of "Moderate Buy" from AnalystsVir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seven analysts that are currently covering the company, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and four have assigned a buy recommeMay 26, 2024 | americanbankingnews.comVir Biotechnology (NASDAQ:VIR) Earns Buy Rating from HC WainwrightMay 25, 2024 | americanbankingnews.comHead to Head Review: Iovance Biotherapeutics (NASDAQ:IOVA) vs. Vir Biotechnology (NASDAQ:VIR)May 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vir Biotechnology on Promising CHD and CHB Program ProspectsMay 24, 2024 | markets.businessinsider.comEvaluating Vir Biotechnology: Insights From 5 Financial AnalystsMay 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vir Biotechnology on Promising HDV Program and Anticipated Trial ResultsMay 24, 2024 | marketbeat.comPanagora Asset Management Inc. Buys New Shares in Vir Biotechnology, Inc. (NASDAQ:VIR)Panagora Asset Management Inc. purchased a new position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) in the fourth quarter, according to its most recent filing with the SEC. The firm purchased 94,516 shares of the company's stock, valued at approximately $951,000. Panagora AssetMay 23, 2024 | finance.yahoo.comVir Biotechnology to Host 2024 Annual Meeting of StockholdersMay 23, 2024 | businesswire.comVir Biotechnology to Host 2024 Annual Meeting of StockholdersMay 22, 2024 | finance.yahoo.comMultiple Abstracts Highlighting Vir Biotechnology’s Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024May 21, 2024 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Stock Price Up 3.4%Vir Biotechnology (NASDAQ:VIR) Stock Price Up 3.4%May 21, 2024 | businesswire.comVir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024May 13, 2024 | prnewswire.comBrii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 StudiesMay 9, 2024 | marketbeat.comResearch Analysts Offer Predictions for Vir Biotechnology, Inc.'s FY2024 Earnings (NASDAQ:VIR)Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) - Research analysts at HC Wainwright increased their FY2024 earnings per share estimates for shares of Vir Biotechnology in a research report issued on Tuesday, May 7th. HC Wainwright analyst P. Trucchio now anticipates that the company will postMay 8, 2024 | finance.yahoo.comAnalysts Just Shipped A Stunning Upgrade To Their Vir Biotechnology, Inc. (NASDAQ:VIR) EstimatesMay 7, 2024 | markets.businessinsider.comBuy Rating Affirmed: Anticipated Breakthroughs in Vir Biotechnology’s Clinical PipelineMay 7, 2024 | markets.businessinsider.comDeep Dive Into Vir Biotechnology Stock: Analyst Perspectives (6 Ratings)May 7, 2024 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Receives Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $110.00 price objective on shares of Vir Biotechnology in a research report on Tuesday.May 4, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vir Biotechnology Amid Promising HDV and HBV Treatment MilestonesMay 3, 2024 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Announces Quarterly Earnings ResultsVir Biotechnology (NASDAQ:VIR - Get Free Report) posted its earnings results on Thursday. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.99) by $0.51. The company had revenue of $56.38 million during the quarter, compared to the consensus estimate of $11.71 million. Vir Biotechnology had a negative net margin of 713.69% and a negative return on equity of 34.92%. The firm's revenue for the quarter was down 10.5% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.06) earnings per share.May 3, 2024 | marketbeat.comVir Biotechnology's (VIR) "Buy" Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and set a $15.00 price objective on shares of Vir Biotechnology in a report on Friday.May 3, 2024 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Price Target Raised to $12.00JPMorgan Chase & Co. increased their price objective on shares of Vir Biotechnology from $10.00 to $12.00 and gave the stock a "neutral" rating in a research report on Friday.May 3, 2024 | markets.businessinsider.comHold Rating on Vir Biotechnology Amid Financial Concerns and Clinical Trial UncertaintyMay 3, 2024 | finance.yahoo.comVir Biotechnology, Inc. (NASDAQ:VIR) Q1 2024 Earnings Call TranscriptMay 3, 2024 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Shares Gap Up on Strong EarningsVir Biotechnology (NASDAQ:VIR) Shares Gap Up on Better-Than-Expected EarningsMay 3, 2024 | seekingalpha.comVir Biotechnology Provides Some Hope For Its Beleaguered ShareholdersMay 3, 2024 | finance.yahoo.comVir Biotechnology Inc (VIR) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...May 3, 2024 | finance.yahoo.comQ1 2024 Vir Biotechnology Inc Earnings CallMay 2, 2024 | investorplace.comVIR Stock Earnings: Vir Biotechnology Beats EPS for Q1 2024May 2, 2024 | msn.comVir Biotechnology GAAP EPS of -$0.48 beats by $0.59, revenue of $56.38M beats by $44.67MMay 2, 2024 | businesswire.comVir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 1, 2024 | markets.businessinsider.comVir Biotechnology earnings preview: what Wall Street is expectingApril 30, 2024 | finance.yahoo.comVir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024April 28, 2024 | finance.yahoo.comWith 53% ownership, Vir Biotechnology, Inc. (NASDAQ:VIR) boasts of strong institutional backingApril 26, 2024 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Trading 7.6% Higher Vir Biotechnology (NASDAQ:VIR) Trading Up 7.6%April 26, 2024 | msn.comSouthern policies help level up investment from East AsiaApril 25, 2024 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Hits New 52-Week Low at $7.65Vir Biotechnology (NASDAQ:VIR) Sets New 12-Month Low at $7.65April 20, 2024 | marketbeat.comMirae Asset Global Investments Co. Ltd. Purchases 155,196 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)Mirae Asset Global Investments Co. Ltd. boosted its position in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 268.9% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 212,902 shares of the company's stock after purchasing an additionaApril 18, 2024 | finance.yahoo.comVir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of DirectorsApril 18, 2024 | businesswire.comVir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D.April 16, 2024 | morningstar.comVir Biotechnology IncApril 11, 2024 | finance.yahoo.comVir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024April 11, 2024 | businesswire.comVir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024April 9, 2024 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of "Moderate Buy" by BrokeragesShares of Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) have received a consensus rating of "Moderate Buy" from the seven analysts that are covering the firm, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and four have given a buy recommendatioApril 5, 2024 | insidertrades.comInsider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) CEO Sells 72,995 Shares of Stock Get Vir Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter. Email Address This military-backed stock “owns” AI market (Ad)The AI boom is just getting started. And the real wealth has still to be made… You must read this new presentation from Porter Stansberry. VIR Media Mentions By Week VIR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VIR News Sentiment▼0.320.76▲Average Medical News Sentiment VIR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VIR Articles This Week▼84▲VIR Articles Average Week Get Vir Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ALLO News FATE News REPL News BLUE News HALO News CRSP News KRYS News IBRX News IMVT News SWTX News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VIR) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersBiden Nomination CANCELED?The Freeport SocietyWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vir Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
